Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia

Full text
Show less -
Dal Mas, Caroline [1] ; Nani, Joao V. [1] ; Noto, Cristiano [2, 3] ; Yonamine, Camila M. [1] ; da Cunha, Graccielle Rodrigues [3] ; Mansur, Rodrigo B. [4] ; Ota, Vanessa K. [5] ; Belangero, Sintia Iole [5] ; Cordeiro, Quirino [6] ; Kapczinski, Flavio [7] ; Brietzke, Elisa [3] ; Bressan, Rodrigo A. [3] ; Gadelha, Ary [3] ; Hayashi, Mirian A. F. [1]
Total Authors: 14
[1] Univ Fed Sao Paulo UNIFESP, EPM, Dept Pharmacol, Rua 3 Maio 100, Ed INFAR, 3rd Floor, BR-04044020 Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, PRISMA Program Recognit & Intervent Subjects At R, Sao Paulo - Brazil
[3] Univ Fed Sao Paulo UNIFESP, EPM, Dept Psychiat, Sao Paulo - Brazil
[4] Univ Hlth Network, Toronto Western Hosp, Mood Disorders Psychopharmacol Unit, Toronto, ON - Canada
[5] Univ Fed Sao Paulo UNIFESP, EPM, Dept Morphol & Genet, Sao Paulo - Brazil
[6] ISCMSP, Sao Paulo - Brazil
[7] McMaster Univ, Hamilton, ON - Canada
Total Affiliations: 7
Document type: Journal article
Source: SCHIZOPHRENIA RESEARCH; v. 208, p. 202-208, JUN 2019.
Web of Science Citations: 2

Our previous studies showed reduced Ndel1 enzyme activity in patients with chronic schizophrenia (SCZ), and only a subtle NDEL1 mRNA increases in antipsychotic-naive first-episode psychosis (FEP) individuals compared to matched healthy controls (HC). Aiming to refine the evaluation of Ndel1 enzyme activity in early stages of psychosis, we compared 3 groups composed by (1) subjects at ultra-high-risk (UHR) for psychosis, (2) a cohort comprising antipsychotic-naive FEP individuals (assessed in three moments, at baseline (FEP-0), and after 2 months ( FEP-2 M) and one year (FEP-1Y) of treatment with risperidone), and (3) a HC group. There was no significant difference in Ndel1 enzyme activity between UHR and HC, but this activity was significantly lower in FEP compared to HC. Conversely, Ndel1 activity in HC groups was higher than in FEP even before (FEP-0) or after the treatment with risperidone (FEP-2 M and FEP-1Y). and with progressive decrease of Ndel1 activity and significant improvement of symptoms observed after this treatment. In addition, a positive correlation was observed for Ndel1 activity with clinical symptoms as assessed by PANSS, while a negative correlation was seen for GAF scores. Our results suggest that reductions in Ndel1 activity in FEP may be possibly related to responses to the illness, rather than to the pharmacological effects of antipsychotics, which might be acting essentially in the symptoms suppression. This hypothesis might be further evaluated in prospective long-term follow-up studies with a larger sample cohort. (C) 2019 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 13/13392-4 - Evaluation of the use of analogs of crotamine for diagnosis or therapy
Grantee:Mirian Akemi Furuie Hayashi
Support Opportunities: Regular Research Grants
FAPESP's process: 12/08941-6 - The study of oligopeptidases in schizophrenia
Grantee:Camila Miyagui Yonamine Asanuma
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 11/50740-5 - Prevention in schizophrenia and bipolar disorder from neuroscience to the community: a multiphase, multimodal and translational platform for research and intervention
Grantee:Rodrigo Affonseca Bressan
Support Opportunities: Research Projects - Thematic Grants